On diabetic foot, wound healing, amputation prevention, and the merger of consumer tech with medical devices
A familiar beta-blocker has found an unfamiliar role. Phase 3 data suggest topical esmolol may help diabetic foot ulcers close—and the slowest-healing wounds may be especially interesting.
A new multi-omics preprint uses Mendelian randomization to argue that six circulating miRNAs causally regulate peripheral artery disease in the diabetic foot—and flags metformin as the most translationally tractable repurposing candidate. A nice piece of computational scaffolding, with the usual in-silico caveats.
